Genetic Modification Safety Committee (GMSC). Congratulations on your appointment to the Pharminox GMSC! Marc Hummersone Malcolm Stevens Tracey Bradshaw Shilpa Senapati Charles Matthews Why?
Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.
Congratulations on your appointment to the Pharminox GMSC!
To review/approve the risk assessments for experiments involving genetically modified microorganisms
This is required to notify the HSE that we plan to undertake experiments using genetically modified microorganisms at our premises at Biocity.
What does this entail?
Once yearly meeting (i.e. now) to review current risk assessment and approve it.
Very occasional (maybe once more this year) addition to monthly meeting to approve further projects.
Use of SNB19V/M and U373V/M cells to screen compounds
Over expression of MGMT in cells through stable insertion of MGMT gene into cells making them resistant to temozolomide.
Key Points in risk assessment
Cell lines themselves are low hazard
Advisory Committee on Dangerous Pathogens (ACDP) class 1
Unlikely to cause human disease
We will handle cells at class 2
DNA used for transfection (pcDNA3.1 vector) is non-mobilisable
Cannot be passed on to other micro-organisms, plasmid does not contain relevant genes
Overexpression of MGMT protein will not alter the pathogenicity of cells
Cells already have low pathogenicity and introducing MGMT is unlikely to alter this.